跳至主要内容
临床试验/CTRI/2020/06/026006
CTRI/2020/06/026006已完成未知

Efficacy of Early terlipressin plus albumin therapy in comparison to standard treatment for HRS-AKI in acute-on-chronic liver failure- A randomized open label study

Institute of Liver and Biliary Sciences0 个研究点目标入组 70 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Age 18-65 years
  • 2) ACLF as per APASL criteria
  • 3) AKI at admission as defined by ICA-AKI criteria
  • 4) AKI stage 2/3 at 12 hour of admission

排除标准

  • At Admission:
  • 1) Age <18 years
  • 2) Patients on renal replacement therapy (RRT)
  • 3) Post renal or liver transplantation
  • 4) History of CAD, ischemic cardiomyopathy, PVD, ventricular arrhythmia
  • 5) Decompensated cirrhosis not fulfilling ACLF criteria
  • 6) Cirrhotics with AKI managed as outpatients
  • 7) Grade III/IV HE or Shock requiring inotropes or patients on mechanical ventilator at time of randomization
  • 9) In-hospital new AKI
  • 10) Active urinary sediments - 2+ albumin or above, dysmorphic RBCs
  • 11) Known CKD, obstructive uropathy
  • 12) Lack of informed consent
  • 13) Prior intolerance or S/E to Terlipressin or albumin
  • At 12 Hour before randomization:
  • Regression of AKI ( >0.3 mg/dl) above baseline after IV albumin (20% 40 gm) + IV Crystalloids 500 ml therapy for 12 hours

研究者

相似试验